U.S. Pharmacist



Sandoz Receives Approval for New Omnitrope Indication

By Staff


US Pharm. 2010;35(10):102. 

Sandoz announced that the FDA has approved its human growth hormone omnitrope (somatropin [rDNA origin] for injection) for the treatment of idiopathic short stature (ISS). Recently, omnitrope was also approved for the treatment of children with growth failure due to Prader-Willi syndrome and of those who are small for gestational age. The term ISS describes children or adolescents who are very short compared with others of their age, but have no identifiable disorder or no evidence of systemic, endocrine, nutritional, or chromosomal abnormalities. Omnitrope was originally approved for pediatric patients who have growth failure and for replacement therapy in adults with growth hormone deficiency.

The company also announced the launch of the Sandoz Patient Assistance Program to help eligible patients gain access to omnitrope, part of a suite of services designed to help enhance affordability for patients taking the drug. These services include in-home injection training and the “Save As You Grow” program, which can save patients out-of-pocket costs.

U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Copyright © 2000 - 2016 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.